Serum Institute already has two deals of 100 million each to supply the Oxford-AstraZeneca and the Novavax vaccine to Gavi-Covax at $3 per dose.
'Safety is my first priority.' 'I need to ensure that any drug or vaccine that our citizens get is first safe.'
The Covishield maker's forte throughout the past half a century has been a combination of affordable vaccines and high volumes. Its tetanus, diphtheria and measles vaccines are known throughout the world, reports Sohini Das.
'We are hoping by March, the government allows us to export and give it to the private market.'
Although residential sales faced a major set back in Q2, they made a comeback with help of pent up demand.
'The government should put the whole road map together for the vaccine and decide how industry can support...' 'They should allow the private sector to vaccinate.'
The expert committee sought more information from Serum Institute regarding the Oxford-AstraZeneca vaccine.
In December, over 1.7 million people have checked in over the weekends.
The primary objective was to get the adult vaccine as children rarely have a severe form of the disease. Once schools reopen, the demand for vaccines for children under 12 may soar.
Each of the larger states may need less than Rs 10,000 crore each to finance the exercise.
iPhone SE 2020 is one of the popular phones like Apple 11, which is the biggest seller in the domestic market.
At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for the Covishield.
V G Siddhartha's wife has the support of the employees. But the challenges ahead of her are tough.
The vaccine would be first made available to the vulnerable population and eventually, it would be available in the private market for all.
Wistron, which earlier pegged the losses at Rs 437 crore, later notified the Taiwan stock exchange that the total losses were around Rs 50 crore.
Bharat Biotech is in the middle of conducting a phase 3 trial with 22,000 subjects.
A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval, reports Sohini Das.
India's first mRNA platform-based vaccine will remain stable at 2-8 degrees Celsius while Pfizer-BioNTech's vaccine needs minus 70 degrees Celsius and Moderna vaccine can remain stable for six months at minus 20 degrees Celsius, reports Sohini Das.
'Our client is suffering due to the ill-effects of the vaccine. He has to be compensated for his suffering. Further, a detailed investigation has to be done on the Covishield vaccine and its side-effects,' says the volunteer's advocate.
The PM's visit would signal a strong intent towards making sure India becomes a beneficiary as vaccines become a massively traded commodity in the coming years.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances